EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

European Expert Panel Consensus on Outpatient Administration of Teclistamab and Talquetamab in Patients With Multiple Myeloma: Feasibility, Key Considerations, and Future Directions

Thomas Lund iD, Cyrus Khandanpour, Sébastien Anguille, Jens Kisro, Maria Theresa Krauth, Johan Lund, Inger Nijhof, Enrique M Ocio, Elena Zamagni, Matthieu Javelot, Claire Albrecht, Cristina Entrala Cerezo und 1 weitere

European Journal of Haematology · 2025-10 · 115 (4) · 358-366

DOI: 10.1111/ejh.14444 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Haematology, online erschienen am 26.06.2025. Verfasst von Thomas Lund und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Odense University Hospital, Odense, Denmark. Hauptthemen laut MEDLINE: Multiple Myeloma, Antibodies, Bispecific, Ambulatory Care, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Johnson & Johnson Global Services LLC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Teclistamab and talquetamab treatments are typically initiated in a hospital due to the potential risk of cytokine release syndrome. However, emerging data support the potential for outpatient administration (i.e., administration without overnight hospital admission). An expert consensus survey and meeting were conducted among European specialists in multiple myeloma treatment to evaluate current and future outpatient administration with teclistamab and talquetamab in clinical practice.

Methods

All experts completed a 17‐question survey, participated in an individual follow‐up call, and attended an online consensus meeting in September 2024.

Results

There was strong agreement that outpatient treatment with teclistamab and talquetamab is feasible, with implementation already seen in some centers. Factors identified as potential criteria to define patient eligibility include cognitive status, caregiver presence, and distance from the hospital. While outpatient administration is not yet widely adopted due to limited experience with bispecific antibodies, the expert panel expects up to 50% of patients receiving teclistamab and talquetamab could be treated in an outpatient setting within 3 years.

Conclusions

Sharing best practices, robust protocol development, and evidence from clinical trials and real‐world experience will support the implementation of outpatient treatment with bispecific antibodies, which could relieve hospital resources and improve patients' treatment experience.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaAntibodies, BispecificAmbulatory CareAntineoplastic Agents, ImmunologicalHumansOutpatientsEuropeTreatment Outcome

Stichwörter der Autor:innen

Europeantibodiesbispecificconsensushematologymultiple myelomaoutpatientstalquetamabteclistamab

Substanzen

Antibodies, BispecificAntineoplastic Agents, Immunologicaltalquetamab

Autor:innen und Institutionen

  • Department of Hematology, Odense University Hospital, Odense, Denmark.
  • Centre for Innovative Medical Technology (CIMT), Odense, Denmark.
  • University Hospital Schleswig-Holstein and University Cancer Center Schleswig-Holstein, University of Lübeck, Lübeck, Germany.
  • Division of Hematology, Antwerp University Hospital, Edegem, Belgium.
  • Lübecker Onkologische Schwerpunktpraxis, Lübeck, Germany.
  • Department of Medicine I, Division Hematology and Hemostaseology, Medical University Vienna, Vienna, Austria.

ORCID-Profile: Thomas Lund

Förderung

  • Johnson & Johnson Global Services LLC

Zitieren

APA

Lund, T., Khandanpour, C., Anguille, S., Kisro, J., Krauth, M. T., Lund, J., Nijhof, I., Ocio, E. M., Zamagni, E., Javelot, M., Albrecht, C., Cerezo, C. E., & Perrot, A. (2025). European Expert Panel Consensus on Outpatient Administration of Teclistamab and Talquetamab in Patients With Multiple Myeloma: Feasibility, Key Considerations, and Future Directions. European Journal of Haematology, 115(4), 358-366. https://doi.org/10.1111/ejh.14444

Vancouver

Lund T, Khandanpour C, Anguille S, Kisro J, Krauth MT, Lund J, et al. European Expert Panel Consensus on Outpatient Administration of Teclistamab and Talquetamab in Patients With Multiple Myeloma: Feasibility, Key Considerations, and Future Directions. European Journal of Haematology. 2025;115(4):358-366. doi:10.1111/ejh.14444

BibTeX
@article{Lund2025,
  author = {Lund, Thomas and Khandanpour, Cyrus and Anguille, Sébastien and Kisro, Jens and Krauth, Maria Theresa and Lund, Johan and Nijhof, Inger and Ocio, Enrique M and Zamagni, Elena and Javelot, Matthieu and Albrecht, Claire and Cerezo, Cristina Entrala and Perrot, Aurore},
  title = {European Expert Panel Consensus on Outpatient Administration of Teclistamab and Talquetamab in Patients With Multiple Myeloma: Feasibility, Key Considerations, and Future Directions},
  journal = {European Journal of Haematology},
  year = {2025},
  volume = {115},
  number = {4},
  pages = {358--366},
  doi = {10.1111/ejh.14444}
}
Kostenlos starten →